Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Testim Testosterone Lawsuit Filed On Behalf Of Maryland Man Who Suffered A Heart Attack And Stroke Allegedly From Using Testim, By Alonso Krangle LLP
  • USA - English


News provided by

Alonso Krangle LLP

Feb 02, 2015, 03:00 ET

Share this article

Share toX

Share this article

Share toX

To discuss filing a testosterone therapy lawsuit, please contact Alonso Krangle LLP at 1-800-403-6191 or visit our website, http://www.FightForVictims.com
To discuss filing a testosterone therapy lawsuit, please contact Alonso Krangle LLP at 1-800-403-6191 or visit our website, http://www.FightForVictims.com

To discuss filing a testosterone therapy lawsuit, please contact Alonso Krangle LLP at 1-800-403-6191 or visit our website, http://www.FightForVictims.com

Post this

New York, NY (PRWEB) February 02, 2015 -- Alonso Krangle LLP has filed a Testim Testosterone lawsuit on behalf of a Maryland resident who suffered an ischemic stroke and a heart attack allegedly as a result of taking Testim a low testosterone therapy treatment drug. The “Low T” therapy Testim lawsuit alleges the 62 year old man used the testosterone medication from August 2012 to July 2013. He suffered a stroke on or about April 2013 and then a heart attack in July 2013. The suit contends both cardiac events are due to his use of Testim. He was 62 years old at the time. The testosterone lawsuit adds that Auxilium Pharmaceuticals, which manufactures Testim, allegedly misrepresented the testosterone product as being safe and effective to treat “Low T” when in fact it causes serious medical problems. The Testim testosterone lawsuit complaint also accuses Auxilium of engaging in an aggressive consumer advertising campaign for Testim yet failing to provide appropriate warnings for consumers and health care providers about the potential risks or suspected rates of heart attack, stroke, deep vein thrombosis, pulmonary embolism or death as a result of using the testosterone product. As stated in a New York Times article, men who take take testosterone therapt drugs, "have been found to have higher rates of heart problems in some studies." The testosterone lawsuit was filed on January 19 in the U.S. District Court, District of Northern Illinois. (1:15-cv-00494) Filed Complaint
[ fda.gov/Drugs/DrugSafety/ucm383904.htm FDA Dec 2014]
[ fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsand
Providers/ucm161874.htm FDA Dec 2014 ]
[ http://www.nytimes.com/2014/09/18/health/testosterone-drugs-fda.html?_r=0 ,
New York Times, September 17, 2014 ]

Lawsuit filings over testosterone replacement therapy products have been on the rise since the U.S. Food and Drug Administration (FDA) announced its investigation in January 2014 into the safety and effectiveness of all FDA-approved testosterone gels, creams, patches and injections that treat hypogonadism, or low testosterone levels in men with an underlying medical condition. The federal agency said it was launching its investigation after reviewing two observational studies. The first study, published in the Journal of the American Medical Association in November 2013, suggested that older men with underlying heart disease were at a 30 percent increased risk of stroke, heart attack and death if they took testosterone replacement therapy products. The second study reported an increased risk of heart attack in older men, as well as in younger men with pre-existing heart disease, who filed a testosterone prescription. According to the study, the heart attack risk for men 65 or older rose two-fold during the first 90 days following the first prescription. Younger men with pre-existing heart problems faced a two- to three-fold increased risk of heart attack in the first 90 days following their first prescription.

As pretrial proceedings for the testosterone litigation are underway in the U.S. District Court, District of Northern Illinois, court records show that low testosterone lawsuit filings continue to increase. The complaints filed over testosterone products such as AndroGel, Androderm, and Testim have risen from 274 in December to 282 as of January 15. The lawsuits have been filed on behalf of men, or their survivors who allege that they have suffered such side effects as blood clots, heart attacks, strokes and death after using prescription testosterone products including:

• AndroGel
• Androderm
• Axiron
• Delatestryl
• Fortesta
• Depo-Testosterone
• Testim

[jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-January-15-2015.pdf, January 15, 2015]
[jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-December-15-2014.pdf, December 15, 2014]

Other Testosterone Lawsuits Being Filed
In addition to the Northern Illinois federal court, testosterone replacement therapy complaints are being filed nationwide in state courts, including California, Indiana, Missouri and Pennsylvania. On January 7, U.S. District Court Judge Matthew Kennelly, who is presiding over the testosterone litigation in the Northern Illinois federal court, issued a Case Management Order (CMO) that stated his goal to coordinate state court testosterone lawsuits with the federal litigation. To that end, Judge Kennelly appointed four plaintiffs’ attorneys to serve as liaisons between the state courts and the Northern Illinois federal court. Judge Kennelly wrote in his CMO that he wanted to coordinate parallel and overlapping proceedings in the state and federal cases as a way of reducing costs and avoiding an unnecessary duplication of efforts. Judge Kennelly ordered the liaison attorneys to maintain a comprehensive and updated list of all low testosterone complaints filed in state courts and have regular contact with plaintiffs’ attorneys in the state courts regarding the latest developments in the state court and federal court cases. (In re: Testosterone Replacement Therapy Product Therapy Litigation – MDL No. 2545)

Learn More About Filing A Low Testosterone Testim Lawsuit
If you or someone you care about suffered a heart attack, stroke or other heart problem while undergoing testosterone treatment with a product like AndroGel, Androderm, Testim or Axiron, you may be eligible to file a low testosterone treatment therapy lawsuit against the maker of the medication. To learn more about the legal options available to you or how to file a low testosterone Testim lawsuit, please contact the testosterone therapy lawyers at Alonso Krangle LLP by filling out our online form or calling 1-800-403-6191.

About Alonso Krangle LLP And Filing A Testosterone Therapy Lawsuit
Andres Alonso and David Krangle, attorneys with almost 40 years of collective legal experience, have focused their law practice on the handling of significant personal injury cases, defective drug and medical device litigation, construction site accidents, nursing home abuse, medical negligence, qui tam/whistleblower actions and consumer fraud cases. A nationwide law firm representing injured victims throughout the U.S., Alonso Krangle LLP is headquartered in Long Island, New York, with offices in New York City, and New Jersey. To discuss filing a testosterone therapy lawsuit, please contact Alonso Krangle LLP at 1-800-403-6191 or visit our website, http://www.FightForVictims.com

David Krangle, Alonso Krangle LLP, http://www.fightforvictims.com, +1 800-403-6191, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.